Sapu BioScience and Cromos Pharma initiating P201 - A Registrational trial for OT-101 in Pancreatic Cancer

Stock Information for Oncotelic Therapeutics Inc

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Oncotelic Therapeutics Inc

Oncotelic Therapeutics, Inc. to Sell Its Necroptosis Cancer Therapy Assets to Mosaic ImmunoEngineering, Inc.
Linkage of Cancer and Lupus in Gliomas Patients
Invitation to Participate in STOP-PC Clinical Trial
Oncotelic Therapeutics Announces Clinical Linkage of TGFB2 and IFNGR2 in Pediatric DMG Patients
Oncotelic Therapeutics Announces Opening of GMP Manufacturing Plant
Oncotelic Therapeutics Announces CEO To Discuss Proprietary AI Technology at Ibero-American Chatbot Summit.
Oncotelic Reports Q3 2023 Compared to Q3 2022 Financial Results
Oncotelic Therapeutics, Inc. Awarded Top Cancer Immunotherapy Solutions Provider 2023

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.